• Savara Granted Breakthrough Therapy Designation for Molgradex americanpharmaceuticalreview
    January 07, 2020
    Savara announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP.
  • IMPALA Phase 3 Study of Molgradex Does Not Meet Primary Endpoint americanpharmaceuticalreview
    June 14, 2019
    Savara announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP ...
PharmaSources Customer Service